Meta AnalysisID 6051
灯盏生脉胶囊治疗缺血性脑卒中的新视角：随机对照试验的系统评价和Meta分析
CRD42021238445
1. What is the efficacy of the Dengzhan Shengmai capsule for ischemic stroke? 2. Is it safe to treat ischemic stroke? 3. Does the Dengzhan Shengmai capsule have any effect on cognitive impairment caused by ischemic strok
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6051
- Evidence Id
- 14609
- Core Evidence Id
- 14609
- Source Meta Analysis Id
- 6034
- Herb2 Meta Analysis Id
- HBMA006034
- Crd Id
- CRD42021238445
- Title
- A new perspective of Dengzhan Shengmai capsule in the treatment of ischemic stroke: a systematic review and meta-analysis of randomized controlled trials
- Review Question
- 1. What is the efficacy of the Dengzhan Shengmai capsule for ischemic stroke? 2. Is it safe to treat ischemic stroke? 3. Does the Dengzhan Shengmai capsule have any effect on cognitive impairment caused by ischemic stroke?
- Study Type Included
- Randomized controlled trials (RCTs) were eligible. We included RCTs studying the Dengzhan Shengmai capsule in the acute stage and the convalescence (or sequelae) stage of ischemic stroke. We applied no restrictions regarding the language of publication and combined multiple publications reporting the same trial into one study.
- Condition Being Studied
- Stroke is nervous system damage caused by acute focal injury of the central nervous system. Ischemic stroke is the most common type of stroke and the second most common cause of death and disability in the world. The intervention and treatment of ischemic stroke are of great significance to reduce the recurrence rate and mortality, improve the prognosis of patients and improve the quality of life of patients. Dengzhan Shengmai capsule is derived from the combination of traditional Chinese medicine Dengzhanhua and Shengmai Powder (Ginseng, Ophiopogon japonicus, Schisandra Chinensis). Studies have shown that the drug has the functions of scavenging oxygen free radicals, reducing reperfusion injury after cerebral ischemia, anti-inflammatory and anti-oxidation, anti-platelet aggregation, and anticoagulation. Recent studies have found that Dengzhan Shengmai capsule can also improve cognitive function after ischemic stroke. Although similar systematic reviews (only included RCTs before May 2016) on the Dengzhan Shengmai capsule in the treatment of ischemic stroke have shown its efficacy, there is no meta-analysis on improving cognitive dysfunction, lipid metabolism, hemorheology. Besides, in recent years, there have been many new RCTs of ischemic stroke on the Dengzhan Shengmai capsule. Thus, we will conduct a new systematic review and meta-analysis.
- Participant
- Participants with ischemic stroke were included. They should be diagnosed by brain Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) to confirm infarction and exclude hemorrhage regardless of their age, sex, race, or disease stage.
- Animal
- Human Disease Modelled
- Intervention
- Chinese patent medicine Dengzhan Shengmai capsule or combined with conventional medicine was regarded as the intervention, regardless of its dosage and duration.
- Comparator Control
- Comparisons include placebo or conventional medicine.
- Main Outcome
- Primary outcomes include the following: 1. The global neurological deficit, e.g., the National Institutes of Health Stroke Scale (NIHSS); the Neurological Function Deficit Score (NFDS). 2. All-cause mortality. 3. Recurrence of stoke. 4. Cardiovascular events. 5. Dependence assessed by Barthel Index (BI) scores and modified Rankin Scale. Measures of effect At the end of the scheduled treatment or follow-up period.
- Outcome Measure
- Additional Outcome
- Secondary outcomes include the following: 1. Cognitive function measured by scales. 2. Related hemorheology and lipid metabolism outcomes. 3. Quality of life. 4. Adverse events. Measures of effect At the end of the scheduled treatment or follow-up period.
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Brain Ischemia; Drugs, Chinese Herbal; Humans; Ischemic Stroke; Randomized Controlled Trials as Topic; Stroke; dengzhan shengmai capsule
- Contact
- Xueyan Liu [email protected]
- Organisational Affiliation
- Fujian medical university; Fujian university of traditional Chinese medicine; Professional Committee for Post-listing Re-evaluation of the World Federation of Chinese Medicine Societies. http://www.fjmu.edu.cn/
- Funding Source
- This study was supported by the Startup Fund for scientific research, Fujian Medical University (Grant number: 2019QH1297), and the Scientific Foundation of Fuzhou City (Grant number: 2020-WS-57)
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2021-02-20
- Registration Date
- 2021-03-18
- Anticipated Start Date
- 2021-01-01
- Anticipated Completion Date
- 2021-04-01
- Title Cn
- 灯盏生脉胶囊治疗缺血性脑卒中的新视角：随机对照试验的系统评价和Meta分析
- Title En
- A new perspective of Dengzhan Shengmai capsule in the treatment of ischemic stroke: a systematic review and meta-analysis of randomized controlled trials
- Bilingual Status
- complete